IQV IQVIA Holdings Inc. Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
13:00
Aug 05
Aug 05
DSA bookings and book-to-bill hit their highest level in nearly four years (Q3 2022), signalling the start of an industry-wide recovery in preclinical demand, earlier than many expected. — Strong DSA demand may indicate a broader CRO recovery trend; competitors may also see improvements later in 2026.
MED
09:58
Aug 03
Aug 03
A news wire reports a broad list of price target increases from multiple banks across dozens.
A news wire reports a broad list of price target increases from multiple banks across dozens of stocks, with no explicit directional calls or personal market views expressed.
13:00
Jul 28
Jul 28
Exceptionally positive tone with all metrics exceeding guidance, strong bookings, improving market conditions, and raised full-year guidance across revenue, EBITDA, and EPS.
HIGH
03:01
May 06
May 06
The author compares current semiconductor mania to the COVID-era biopharma bubble.
The author compares current semiconductor mania to the COVID-era biopharma bubble, warning that overextrapolation of innovation led to massive losses, implying similar risk for semis now.
HIGH
02:56
May 06
May 06
The author compares current semiconductor mania to the COVID-era life sciences bubble.
The author compares current semiconductor mania to the COVID-era life sciences bubble, warning that overhyped assumptions could lead to a similar crash.
HIGH
13:00
May 05
May 05
Management raised EPS guidance and highlighted strong acceleration in organic growth, record pipelines, and positive demand indicators, signaling confidence in continued momentum.
HIGH
00:52
Apr 03
Apr 03
The tweet implies a negative outlook for contract research organizations.
HIGH
22:00
Mar 04
Mar 04
Veeva is taking market share from IQVIA in the CRM space for top-20 pharma accounts.
HIGH
04:33
Feb 17
Feb 17
A sell-side analyst has lowered their price target on IQV.
A sell-side analyst has lowered their price target on IQV, signaling a bearish forward-looking view on the stock's potential.
MED
14:00
Feb 05
Feb 05
Guidance for 2026 is positive, with expected revenue growth of ~6% at the midpoint (~$17.23B). The company expects the demand environment to continue improving, driven by stabilization in biotech funding and strong demand for its AI-enabled offerings.
HIGH
22:00
Nov 20
Nov 20
Veeva expects Crossix to potentially match the size of the entire CRM suite by 2030, signaling significant growth in digital marketing measurement. — This implies that the shift to digital marketing measurement is accelerating at the expense of traditional CRM spend, impacting both IQVIA and Salesforce.
HIGH
About IQV Analyst Coverage
Buzzberg tracks IQV (IQVIA Holdings Inc.) across 4 sources. 0 bullish vs 0 bearish calls from 8 analysts. Sentiment: evenly split. 11 total trade ideas tracked. Latest voices: Birgit Girshick, DeItaone, Ari Bousbib.